AtaiBeckley (ATAI) Shares Outstanding (Diluted Average) (2021 - 2026)
AtaiBeckley (ATAI) recorded quarterly Shares Outstanding (Diluted Average) of $357.4 million in Q1 2026, up 57.78% quarter-over-quarter from $226.5 million in Q4 2025, and up 102.77% on a YoY basis from $176.3 million in Q1 2025.
AtaiBeckley (ATAI) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
AtaiBeckley's Shares Outstanding (Diluted Average) history runs 3 years deep, the most recent figure standing at $357.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 102.77% year-over-year to $357.4 million; the TTM figure through Mar 2026 stood at $357.4 million (up 102.77% YoY), while the FY2025 annual figure was $226.5 million, up 41.44% from the prior year.
- Shares Outstanding (Diluted Average) was $357.4 million for Q1 2026 at AtaiBeckley, up from $226.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $217.6 million in Q3 2025 to a low of $121.4 million in Q1 2021.
- The 5-year median for Shares Outstanding (Diluted Average) is $155.8 million (2023), against an average of $158.6 million.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Diluted Average) surged 41.44% in 2025, then surged 102.77% in 2026.
- A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $160.2 million in 2024, then surged by 41.44% to $226.5 million in 2025, then soared by 57.78% to $357.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $357.4 million (Q1 2026), $226.5 million (Q4 2025), and $176.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | 357.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 357.42 Mn |
| Dec 31, 2025 | 226.53 Mn |
| Sep 30, 2025 | 217.60 Mn |
| Jun 30, 2025 | 196.56 Mn |
| Mar 31, 2025 | 176.27 Mn |
| Mar 31, 2025 | 176.27 Mn |
| Dec 31, 2024 | 160.16 Mn |
| Mar 31, 2024 | 158.89 Mn |
| Dec 31, 2023 | 158.83 Mn |
| Sep 30, 2023 | 177.57 Mn |
| Jun 30, 2023 | 155.79 Mn |
| Mar 31, 2023 | 155.79 Mn |
| Dec 31, 2022 | 155.72 Mn |
| Sep 30, 2022 | 156.61 Mn |
| Jun 30, 2022 | 153.97 Mn |
| Mar 31, 2022 | 153.53 Mn |
| Dec 31, 2021 | 138.27 Mn |
| Sep 30, 2021 | 134.33 Mn |
| Jun 30, 2021 | 125.80 Mn |
| Mar 31, 2021 | 121.37 Mn |